Adrenal cortex renewal in health and disease.
Journal
Nature reviews. Endocrinology
ISSN: 1759-5037
Titre abrégé: Nat Rev Endocrinol
Pays: England
ID NLM: 101500078
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
accepted:
30
03
2021
pubmed:
21
5
2021
medline:
24
9
2021
entrez:
20
5
2021
Statut:
ppublish
Résumé
Resident progenitor and/or stem cell populations in the adult adrenal cortex enable cortical cells to undergo homeostatic renewal and regeneration after injury. Renewal occurs predominantly in the outer layers of the adrenal gland but newly formed cells undergo centripetal migration, differentiation and lineage conversion in the process of forming the different functional steroidogenic zones. Over the past 10 years, advances in the genetic characterization of adrenal diseases and studies of mouse models with altered adrenal phenotypes have helped to elucidate the molecular pathways that regulate adrenal tissue renewal, several of which are fine-tuned via complex paracrine and endocrine influences. Moreover, the adrenal gland is a sexually dimorphic organ, and testicular androgens have inhibitory effects on cell proliferation and progenitor cell recruitment in the adrenal cortex. This Review integrates these advances, including the emerging role of sex hormones, into existing knowledge on adrenocortical cell renewal. An in-depth understanding of these mechanisms is expected to contribute to the development of novel therapies for severe endocrine diseases, for which current treatments are unsatisfactory.
Identifiants
pubmed: 34011989
doi: 10.1038/s41574-021-00491-4
pii: 10.1038/s41574-021-00491-4
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
421-434Subventions
Organisme : Worldwide Cancer Research
ID : 18-0437
Pays : United Kingdom
Références
Bandiera, R., Sacco, S., Vidal, V. P. I., Chaboissier, M. C. & Schedl, A. Steroidogenic organ development and homeostasis: a WT1-centric view. Mol. Cell. Endocrinol. 408, 145–155 (2015).
pubmed: 25596547
doi: 10.1016/j.mce.2015.01.009
Zubair, M., Ishihara, S., Oka, S., Okumura, K. & Morohashi, K. Two-step regulation of Ad4BP/SF-1 gene transcription during fetal adrenal development: initiation by a Hox-Pbx1-Prep1 complex and maintenance via autoregulation by Ad4BP/SF-1. Mol. Cell. Biol. 26, 4111–4121 (2006).
pubmed: 16705164
pmcid: 1489093
doi: 10.1128/MCB.00222-06
Zubair, M., Parker, K. L. & Morohashi, K. Developmental links between the fetal and adult zones of the adrenal cortex revealed by lineage tracing. Mol. Cell. Biol. 28, 7030–7040 (2008).
pubmed: 18809574
pmcid: 2593385
doi: 10.1128/MCB.00900-08
Bandiera, R. et al. WT1 maintains adrenal-gonadal primordium identity and marks a population of AGP-like progenitors within the adrenal gland. Dev. Cell 27, 5–18 (2013).
pubmed: 24135228
pmcid: 4032791
doi: 10.1016/j.devcel.2013.09.003
Wood, M. A. et al. Fetal adrenal capsular cells serve as progenitor cells for steroidogenic and stromal adrenocortical cell lineages in M. musculus. Development 140, 4522–4532 (2013).
pubmed: 24131628
pmcid: 3817941
doi: 10.1242/dev.092775
Engeland, W. C., Ennen, W. B., Elayaperumal, A., Durand, D. A. & Levay-Young, B. K. Zone-specific cell proliferation during compensatory adrenal growth in rats. Am. J. Physiol. Metab. 288, E298–E306 (2005).
Beuschlein, F. et al. Steroidogenic factor-1 is essential for compensatory adrenal growth following unilateral adrenalectomy. Endocrinology 143, 3122–3135 (2002).
pubmed: 12130578
doi: 10.1210/endo.143.8.8944
Holzwarth, M. A., Shinsako, J. & Dallman, M. F. Adrenal regeneration. Time course, effect of hypothalamic hemi-islands and response to unilateral adrenalectomy. Neuroendocrinology 31, 168–176 (1980).
pubmed: 6251394
doi: 10.1159/000123069
Greep, R. O. & Deane, H. W. Histological, cytochemical and physiological observations on the regeneration of the rat’s adrenal gland following enucleation. Endocrinology 45, 42–56 (1949).
pubmed: 18152108
doi: 10.1210/endo-45-1-42
Grabek, A. et al. The adult adrenal cortex undergoes rapid tissue renewal in a sex-specific manner. Cell Stem Cell 25, 290–296.e2 (2019).
pubmed: 31104943
doi: 10.1016/j.stem.2019.04.012
Bergmann, O. et al. Dynamics of cell generation and turnover in the human heart. Cell 161, 1566–1575 (2015).
pubmed: 26073943
doi: 10.1016/j.cell.2015.05.026
Magrassi, L., Leto, K. & Rossi, F. Lifespan of neurons is uncoupled from organismal lifespan. Proc. Natl Acad. Sci. USA 110, 4374–4379 (2013).
pubmed: 23440189
doi: 10.1073/pnas.1217505110
Simons, B. D. & Clevers, H. Stem cell self-renewal in intestinal crypt. Exp. Cell Res. 317, 2719–2724 (2011).
pubmed: 21787769
doi: 10.1016/j.yexcr.2011.07.010
Chang, S. P. et al. Cell proliferation, movement and differentiation during maintenance of the adult mouse adrenal cortex. PLoS ONE 8, e81865 (2013).
pubmed: 24324726
pmcid: 3852665
doi: 10.1371/journal.pone.0081865
Basham, K. J. et al. A ZNRF3-dependent Wnt/β-catenin signaling gradient is required for adrenal homeostasis. Genes Dev. 33, 209–220 (2019).
pubmed: 30692207
pmcid: 6362817
doi: 10.1101/gad.317412.118
Mitani, F., Mukai, K., Miyamoto, H., Suematsu, M. & Ishimura, Y. The undifferentiated cell zone is a stem cell zone in adult rat adrenal cortex. Biochim. Biophys. Acta 1619, 317–324 (2003).
pubmed: 12573491
doi: 10.1016/S0304-4165(02)00490-7
Zajicek, G., Ariel, I. & Arber, N. The streaming adrenal cortex: direct evidence of centripetal migration of adrenocytes by estimation of cell turnover rate. J. Endocrinol. 111, 477–482 (1986).
pubmed: 3805971
doi: 10.1677/joe.0.1110477
Freedman, B. D. et al. Adrenocortical zonation results from lineage conversion of differentiated zona glomerulosa cells. Dev. Cell 26, 666–673 (2013).
pubmed: 24035414
pmcid: 3791142
doi: 10.1016/j.devcel.2013.07.016
Belgorosky, A., Baquedano, M. S., Guercio, G. & Rivarola, M. A. Expression of the IGF and the aromatase/estrogen receptor systems in human adrenal tissues from early infancy to late puberty: implications for the development of adrenarche. Rev. Endocr. Metab. Disord. 10, 51–61 (2009).
pubmed: 18792783
doi: 10.1007/s11154-008-9105-1
King, P., Paul, A. & Laufer, E. Shh signaling regulates adrenocortical development and identifies progenitors of steroidogenic lineages. Proc. Natl Acad. Sci. USA 106, 21185–21190 (2009).
pubmed: 19955443
doi: 10.1073/pnas.0909471106
Huang, C.-C. J., Miyagawa, S., Matsumaru, D., Parker, K. L. & Yao, H. H.-C. Progenitor cell expansion and organ size of mouse adrenal is regulated by sonic hedgehog. Endocrinology 151, 1119–1128 (2010).
pubmed: 20118198
pmcid: 2840682
doi: 10.1210/en.2009-0814
Finco, I., Lerario, A. M. & Hammer, G. D. Sonic hedgehog and WNT signaling promote adrenal gland regeneration in male mice. Endocrinology 159, 579–596 (2018).
pubmed: 29211850
doi: 10.1210/en.2017-03061
Walczak, E. M. et al. Wnt signaling inhibits adrenal steroidogenesis by cell-autonomous and non-cell-autonomous mechanisms. Mol. Endocrinol. 28, 1471–1486 (2014).
pubmed: 25029241
pmcid: 4154239
doi: 10.1210/me.2014-1060
Val, P., Martinez-Barbera, J. P. & Swain, A. Adrenal development is initiated by Cited2 and Wt1 through modulation of Sf-1 dosage. Development 134, 2349–2358 (2007).
pubmed: 17537799
doi: 10.1242/dev.004390
Wilhelm, D. & Englert, C. The Wilms tumor suppressor WT1 regulates early gonad development by activation of Sf1. Genes Dev. 16, 1839–1851 (2002).
pubmed: 12130543
pmcid: 186395
doi: 10.1101/gad.220102
Steenblock, C. et al. Isolation and characterization of adrenocortical progenitors involved in the adaptation to stress. Proc. Natl Acad. Sci. USA 115, 12997–13002 (2018).
pubmed: 30514817
doi: 10.1073/pnas.1814072115
Steenblock, C. et al. Adrenal cortical and chromaffin stem cells: is there a common progeny related to stress adaptation? Mol. Cell. Endocrinol. 441, 156–163 (2017).
pubmed: 27637345
doi: 10.1016/j.mce.2016.09.011
Ching, S. & Vilain, E. Targeted disruption of sonic hedgehog in the mouse adrenal leads to adrenocortical hypoplasia. Genesis 47, 628–637 (2009).
pubmed: 19536807
doi: 10.1002/dvg.20532
Bourdeau, I. et al. Primary pigmented nodular adrenocortical disease: paradoxical responses of cortisol secretion to dexamethasone occur in vitro and are associated with increased expression of the glucocorticoid receptor. J. Clin. Endocrinol. Metab. 88, 3931–3937 (2003).
pubmed: 12915689
doi: 10.1210/jc.2002-022001
Louiset, E. et al. The paradoxical increase in cortisol secretion induced by dexamethasone in primary pigmented nodular adrenocortical disease involves a glucocorticoid receptor-mediated effect of dexamethasone on protein kinase A catalytic subunits. J. Clin. Endocrinol. Metab. 94, 2406–2413 (2009).
pubmed: 19383776
pmcid: 2708955
doi: 10.1210/jc.2009-0031
Kim, A. C. et al. Targeted disruption of β-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development 135, 2593–2602 (2008).
pubmed: 18599507
doi: 10.1242/dev.021493
Zebisch, M. et al. Structural and molecular basis of ZNRF3/RNF43 transmembrane ubiquitin ligase inhibition by the Wnt agonist R-spondin. Nat. Commun. 4, 2787 (2013).
pubmed: 24225776
pmcid: 3905715
doi: 10.1038/ncomms3787
Hao, H. X. et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 485, 195–202 (2012).
pubmed: 22575959
doi: 10.1038/nature11019
Vidal, V. et al. The adrenal capsule is a signaling center controlling cell renewal and zonation through Rspo3. Genes Dev. 30, 1389–1394 (2016).
pubmed: 27313319
pmcid: 4926862
doi: 10.1101/gad.277756.116
Berthon, A. et al. Constitutive β-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum. Mol. Genet. 19, 1561–1576 (2010).
pubmed: 20106872
doi: 10.1093/hmg/ddq029
Pignatti, E. et al. β-Catenin causes adrenal hyperplasia by blocking zonal transdifferentiation. Cell Rep. 31, 107524 (2020).
pubmed: 32320669
pmcid: 7281829
doi: 10.1016/j.celrep.2020.107524
Berthon, A. et al. WNT/β-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. Hum. Mol. Genet. 23, 889–905 (2014).
pubmed: 24087794
doi: 10.1093/hmg/ddt484
Leng, S. et al. β-Catenin and FGFR2 regulate postnatal rosette-based adrenocortical morphogenesis. Nat. Commun. 11, 1680 (2020).
pubmed: 32245949
pmcid: 7125176
doi: 10.1038/s41467-020-15332-7
Rocha, A. S. et al. The angiocrine factor Rspondin3 is a key determinant of liver zonation. Cell Rep. 13, 1757–1764 (2015).
pubmed: 26655896
doi: 10.1016/j.celrep.2015.10.049
Wang, B., Zhao, L., Fish, M., Logan, C. Y. & Nusse, R. Self-renewing diploid Axin2
pubmed: 26245375
pmcid: 4589224
doi: 10.1038/nature14863
Deane, H. W. & Greep, R. O. A morphological and histochemical study of the rat’s adrenal cortex after hypophysectomy, with comments on the liver. Am. J. Anat. 79, 117–145 (1946).
pubmed: 20994830
doi: 10.1002/aja.1000790104
Gallo-Payet, N. 60 Years of POMC: adrenal and extra-adrenal functions of ACTH. J. Mol. Endocrinol. 56, T135–T156 (2016).
pubmed: 26793988
doi: 10.1530/JME-15-0257
Gorrigan, R. J., Guasti, L., King, P., Clark, A. J. & Chan, L. F. Localisation of the melanocortin-2-receptor and its accessory proteins in the developing and adult adrenal gland. J. Mol. Endocrinol. 46, 227–232 (2011).
pubmed: 21367968
pmcid: 3111094
doi: 10.1530/JME-11-0011
Drelon, C. et al. PKA inhibits WNT signalling in adrenal cortex zonation and prevents malignant tumour development. Nat. Commun. 7, 12751 (2016).
pubmed: 27624192
pmcid: 5027289
doi: 10.1038/ncomms12751
Mathieu, M. et al. Steroidogenic differentiation and PKA signaling are programmed by histone methyltransferase EZH2 in the adrenal cortex. Proc. Natl Acad. Sci. USA 115, E12265–E12274 (2018).
pubmed: 30541888
doi: 10.1073/pnas.1809185115
Xu, K. et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent. Science 338, 1465–1469 (2012).
pubmed: 23239736
pmcid: 3625962
doi: 10.1126/science.1227604
Hornsby, P. J. Adrenarche: a cell biological perspective. J. Endocrinol. 214, 113–119 (2012).
pubmed: 22573830
doi: 10.1530/JOE-12-0022
Dumontet, T. et al. PKA signaling drives reticularis differentiation and sexually dimorphic adrenal cortex renewal. JCI Insight 3, e98394 (2018).
pmcid: 5821213
doi: 10.1172/jci.insight.98394
Mcewan, P. E., Lindop, G. B. M. & Kenyon, C. J. In vivo studies of the control of DNA synthesis in the rat adrenal cortex and medulla. Endocr. Res. 21, 91–102 (1995).
pubmed: 7588422
doi: 10.3109/07435809509030424
McEwan, P. E., Vinson, G. P. & Kenyon, C. J. Control of adrenal cell proliferation by AT1 receptors in response to angiotensin II and low-sodium diet. Am. J. Physiol. Endocrinol. Metab. 276, E303–E309 (1999).
doi: 10.1152/ajpendo.1999.276.2.E303
Nishimoto, K., Harris, R. B. S., Rainey, W. E. & Seki, T. Sodium deficiency regulates rat adrenal zona glomerulosa gene expression. Endocrinology 155, 1363–1372 (2014).
pubmed: 24422541
pmcid: 3959598
doi: 10.1210/en.2013-1999
Clyne, C. D., Nicol, M. R., Macdonald, S. T., Williams, B. C. & Walker, S. W. Angiotensin II stimulates growth and steroidogenesis in zona fasciculata/reticularis cells from bovine adrenal cortex via the AT1 receptor subtype. Endocrinology 132, 2206–2212 (1993).
pubmed: 8386614
doi: 10.1210/endo.132.5.8386614
Coll, A. P. et al. The effects of proopiomelanocortin deficiency on murine adrenal development and responsiveness to adrenocorticotropin. Endocrinology 145, 4721–4727 (2004).
pubmed: 15231703
doi: 10.1210/en.2004-0491
Jefcoate, C. R., Lee, J., Cherradi, N., Takemori, H. & Duan, H. cAMP stimulation of StAR expression and cholesterol metabolism is modulated by co-expression of labile suppressors of transcription and mRNA turnover. Mol. Cell. Endocrinol. 336, 53–62 (2011).
pubmed: 21147196
doi: 10.1016/j.mce.2010.12.006
Xing, Y., Parker, C. R., Edwards, M. & Rainey, W. E. ACTH is a potent regulator of gene expression in human adrenal cells. J. Mol. Endocrinol. 45, 59–68 (2010).
pubmed: 20460446
pmcid: 3725639
doi: 10.1677/JME-10-0006
Lefrançois-Martinez, A. M. et al. Product of side-chain cleavage of cholesterol, isocaproaldehyde, is an endogenous specific substrate of mouse vas deferens protein, an aldose reductase-like protein in adrenocortical cells. J. Biol. Chem. 274, 32875–32880 (1999).
pubmed: 10551851
doi: 10.1074/jbc.274.46.32875
Thomas, M., Keramidas, M., Monchaux, E. & Feige, J.-J. Dual hormonal regulation of endocrine tissue mass and vasculature by adrenocorticotropin in the adrenal cortex. Endocrinology 145, 4320–4329 (2004).
pubmed: 15178648
doi: 10.1210/en.2004-0179
Metherell, L. A. et al. Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. Nat. Genet. 37, 166–170 (2005).
pubmed: 15654338
doi: 10.1038/ng1501
Meimaridou, E. et al. ACTH resistance: genes and mechanisms. Endocr. Dev. 24, 57–66 (2013).
pubmed: 23392095
doi: 10.1159/000342504
Novoselova, T. V. et al. MRAP deficiency impairs adrenal progenitor cell differentiation and gland zonation. FASEB J. 32, fj201701274RR (2018).
doi: 10.1096/fj.201701274RR
Chida, D. et al. Melanocortin 2 receptor is required for adrenal gland development, steroidogenesis, and neonatal gluconeogenesis. Proc. Natl Acad. Sci. USA 104, 18205–18210 (2007).
pubmed: 17989225
doi: 10.1073/pnas.0706953104
Novoselova, T. V. et al. ACTH signalling and adrenal development: lessons from mouse models. Endocr. Connect. 8, R122–R130 (2019).
pubmed: 31189126
pmcid: 6652236
doi: 10.1530/EC-19-0190
Ulrich-Lai, Y. M. et al. Chronic stress induces adrenal hyperplasia and hypertrophy in a subregion-specific manner. Am. J. Physiol. Endocrinol. Metab. 291, E965–E973 (2006).
pubmed: 16772325
doi: 10.1152/ajpendo.00070.2006
Estivariz, F. E., Carino, M., Lowry, P. J. & Jackson, S. Further evidence that N-terminal pro-opiomelanocortin peptides are involved in adrenal mitogenesis. J. Endocrinol. 116, 201–206 (1988).
pubmed: 2832501
doi: 10.1677/joe.0.1160201
de Mendonça, P. O. R. & Lotfi, C. F. P. The proliferative effect of synthetic N-POMC
pubmed: 21167253
doi: 10.1016/j.mce.2010.12.012
Fassnacht, M. et al. N-terminal proopiomelanocortin acts as a mitogen in adrenocortical tumor cells and decreases adrenal steroidogenesis. J. Clin. Endocrinol. Metab. 88, 2171–2179 (2003).
pubmed: 12727972
doi: 10.1210/jc.2002-021318
Coll, A. P. et al. Peripheral administration of the N-terminal pro-opiomelanocortin fragment 1–28 to Pomc
pubmed: 16899584
pmcid: 2638022
doi: 10.1677/joe.1.06749
De Joussineau, C. et al. The cAMP pathway and the control of adrenocortical development and growth. Mol. Cell. Endocrinol. 351, 28–36 (2012).
pubmed: 22019902
doi: 10.1016/j.mce.2011.10.006
Fragoso, M. C. B. V. et al. Cushing’s syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene. J. Clin. Endocrinol. Metab. 88, 2147–2151 (2003).
pubmed: 12727968
doi: 10.1210/jc.2002-021362
Weinstein, L. S. et al. Activating mutations of the stimulatory G protein in the McCune–Albright syndrome. N. Engl. J. Med. 325, 1688–1695 (1991).
pubmed: 1944469
doi: 10.1056/NEJM199112123252403
Taylor, M. J. et al. Chemogenetic activation of adrenocortical Gq signaling causes hyperaldosteronism and disrupts functional zonation. J. Clin. Invest. 130, 83–93 (2020).
pubmed: 31738186
doi: 10.1172/JCI127429
Suthiworachai, C. et al. Identification and functional analysis of six DAX1 mutations in patients with X-linked adrenal hypoplasia congenita. J. Endocr. Soc. 3, 171–180 (2019).
pubmed: 30620004
doi: 10.1210/js.2018-00270
Zanaria, E. et al. An unusual member of the nuclear hormone receptor superfamily responsible for X-linked adrenal hypoplasia congenita. Nature 372, 635–641 (1994).
pubmed: 7990953
doi: 10.1038/372635a0
Muscatelli, F. et al. Mutations in the DAX-1 gene give rise to both X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism. Nature 372, 672–676 (1994).
pubmed: 7990958
doi: 10.1038/372672a0
Vargas, M. C. C. et al. Spontaneous fertility and variable spectrum of reproductive phenotype in a family with adult-onset X-linked adrenal insufficiency harboring a novel DAX-1/NR0B1 mutation. BMC Endocr. Disord. 20, 21 (2020).
pubmed: 32028936
pmcid: 7006140
doi: 10.1186/s12902-020-0500-2
Ito, M., Yu, R. & Jameson, J. L. DAX-1 inhibits SF-1-mediated transactivation via a carboxy-terminal domain that is deleted in adrenal hypoplasia congenita. Mol. Cell. Biol. 17, 1476–1483 (1997).
pubmed: 9032275
pmcid: 231873
doi: 10.1128/MCB.17.3.1476
Crawford, P. A., Dorn, C., Sadovsky, Y. & Milbrandt, J. Nuclear receptor DAX-1 recruits nuclear receptor corepressor N-CoR to steroidogenic factor 1. Mol. Cell. Biol. 18, 2949–2956 (1998).
pubmed: 9566914
pmcid: 110674
doi: 10.1128/MCB.18.5.2949
Xing, Y., Morohashi, K. I., Ingraham, H. A. & Hammer, G. D. Timing of adrenal regression controlled by synergistic interaction between SF1 SUMOylation and Dax1. Development 144, 3798–3807 (2017).
pubmed: 28893949
pmcid: 5675444
Khalfallah, O., Rouleau, M., Barbry, P., Bardoni, B. & Lalli, E. Dax-1 knockdown in mouse embryonic stem cells induces loss of pluripotency and multilineage differentiation. Stem Cell 27, 1529–1537 (2009).
doi: 10.1002/stem.78
Gummow, B. M., Scheys, J. O., Cancelli, V. R. & Hammer, G. D. Reciprocal regulation of a glucocorticoid receptor-steroidogenic factor-1 transcription complex on the Dax-1 promoter by glucocorticoids and adrenocorticotropic hormone in the adrenal cortex. Mol. Endocrinol. 20, 2711–2723 (2006).
pubmed: 16857744
doi: 10.1210/me.2005-0461
Babu, P. S. et al. Interaction between Dax-1 and steroidogenic factor-1 in vivo: Increased adrenal responsiveness to ACTH in the absence of Dax-1. Endocrinology 143, 665–673 (2002).
pubmed: 11796523
doi: 10.1210/endo.143.2.8658
Scheys, J. O., Heaton, J. H. & Hammer, G. D. Evidence of adrenal failure in aging Dax1-deficient mice. Endocrinology 152, 3430–3439 (2011).
pubmed: 21733829
pmcid: 3159781
doi: 10.1210/en.2010-0986
Levasseur, A., St-Jean, G., Paquet, M., Boerboom, D. & Boyer, A. Targeted disruption of YAP and TAZ impairs the maintenance of the adrenal cortex. Endocrinology 158, 3738–3753 (2017).
pubmed: 28938438
pmcid: 5695830
doi: 10.1210/en.2017-00098
Abduch, R. H. et al. Unraveling the expression of the oncogene YAP1, a Wnt/β-catenin target, in adrenocortical tumors and its association with poor outcome in pediatric patients. Oncotarget 7, 84634–84644 (2016).
pubmed: 27705928
pmcid: 5356687
doi: 10.18632/oncotarget.12382
Ménard, A. et al. Targeted disruption of Lats1 and Lats2 in mice impairs adrenal cortex development and alters adrenocortical cell fate. Endocrinology 161, bqaa052 (2020).
pubmed: 32243503
pmcid: 7211035
doi: 10.1210/endocr/bqaa052
Dimartino, J. F. et al. The Hox cofactor and proto-oncogene Pbx1 is required for maintenance of definitive hematopoiesis in the fetal liver. Blood 98, 618–626 (2001).
pubmed: 11468159
doi: 10.1182/blood.V98.3.618
Lichtenauer, U. D. et al. Pre-B-cell transcription factor 1 and steroidogenic factor 1 synergistically regulate adrenocortical growth and steroidogenesis. Endocrinology 148, 693–704 (2007).
pubmed: 17082260
doi: 10.1210/en.2006-0681
Bland, M. L., Fowkes, R. C. & Ingraham, H. A. Differential requirement for steroidogenic factor-1 gene dosage in adrenal development versus endocrine function. Mol. Endocrinol. 18, 941–952 (2004).
pubmed: 14726490
doi: 10.1210/me.2003-0333
Bielohuby, M. et al. Growth analysis of the mouse adrenal gland from weaning to adulthood: time- and gender-dependent alterations of cell size and number in the cortical compartment. Am. J. Physiol. Metab. 293, E139–E146 (2007).
Seale, J. V. et al. Gonadectomy reverses the sexually diergic patterns of circadian and stress-induced hypothalamic-pituitary-adrenal axis activity in male and female rats. J. Neuroendocrinol. 16, 516–524 (2004).
pubmed: 15189326
doi: 10.1111/j.1365-2826.2004.01195.x
Bastida, C. M. et al. Sexual dimorphism of ornithine decarboxylase in the mouse adrenal: influence of polyamine deprivation on catecholamine and corticoid levels. Am. J. Physiol. Endocrinol. Metab. 292, E1010–E1017 (2007).
pubmed: 17148758
doi: 10.1152/ajpendo.00316.2006
Mukai, T. et al. Sexually dimorphic expression of Dax-1 in the adrenal cortex. Genes Cell 7, 717–729 (2002).
doi: 10.1046/j.1365-2443.2002.00556.x
Hershkovitz, L., Beuschlein, F., Klammer, S., Krup, M. & Weinstein, Y. Adrenal 20α-hydroxysteroid dehydrogenase in the mouse catabolizes progesterone and 11-deoxycorticosterone and is restricted to the X-zone. Endocrinology 148, 976–988 (2007).
pubmed: 17122075
doi: 10.1210/en.2006-1100
El Wakil, A., Mari, B., Barhanin, J. & Lalli, E. Genomic analysis of sexual dimorphism of gene expression in the mouse adrenal gland. Horm. Metab. Res. 45, 870–873 (2013).
pubmed: 23921913
doi: 10.1055/s-0033-1349881
Jopek, K. et al. Transcriptome profile of rat adrenal evoked by gonadectomy and testosterone or estradiol replacement. Front. Endocrinol. 8, 26 (2017).
doi: 10.3389/fendo.2017.00026
Pisu, M. G. et al. Sex differences in the outcome of juvenile social isolation on HPA axis function in rats. Neuroscience 320, 172–182 (2016).
pubmed: 26868968
doi: 10.1016/j.neuroscience.2016.02.009
Viau, V., Lee, P., Sampson, J. & Wu, J. A testicular influence on restraint-induced activation of medial parvocellular neurons in the paraventricular nucleus in the male rat. Endocrinology 144, 3067–3075 (2003).
pubmed: 12810563
doi: 10.1210/en.2003-0064
Goel, N., Workman, J. L., Lee, T. T., Innala, L. & Viau, V. Sex differences in the HPA axis. Compr. Physiol. 4, 1121–1155 (2014).
pubmed: 24944032
doi: 10.1002/cphy.c130054
Bentvelsen, F. M., Mcphaul, M. J., Wilson, C. M., Wilson, J. D. & George, F. W. Regulation of immunoreactive androgen receptor in the adrenal gland of the adult rat. Endocrinology 137, 2659–2663 (1996).
pubmed: 8770883
doi: 10.1210/endo.137.7.8770883
Sar, M., Lubahn, D. B., French, F. S. & Wilson, E. M. Immunohistochemical localization of the androgen receptor in rat and human tissues. Endocrinology 127, 3180–3186 (1990).
pubmed: 1701137
doi: 10.1210/endo-127-6-3180
Gannon, A.-L. et al. Androgen receptor signalling in the male adrenal facilitates X-zone regression, cell turnover and protects against adrenal degeneration during ageing. Sci. Rep. 9, 10457 (2019).
pubmed: 31320667
pmcid: 6639311
doi: 10.1038/s41598-019-46049-3
Miyamoto, J. et al. The pituitary function of androgen receptor constitutes a glucocorticoid production circuit. Mol. Cell. Biol. 27, 4807–4814 (2007).
pubmed: 17470551
pmcid: 1951475
doi: 10.1128/MCB.02039-06
Huang, C.-C. J. & Kang, Y. The transient cortical zone in the adrenal gland: the mystery of the adrenal X-zone. J. Endocrinol. 241, R51–R63 (2019).
pubmed: 30817316
pmcid: 6675673
doi: 10.1530/JOE-18-0632
Stein, E., McCrank, E., Schaefer, B. & Goyer, R. Adrenal gland weight and suicide. Can. J. Psychiatry 38, 563–566 (1993).
pubmed: 8242532
doi: 10.1177/070674379303800807
Lam, K. Y., Chan, A. C. L. & Lo, C. Y. Morphological analysis of adrenal glands: a prospective analysis. Endocr. Pathol. 12, 33–38 (2001).
pubmed: 11478266
doi: 10.1385/EP:12:1:33
Nonaka, K. et al. Correlation between telomere attrition of zona fasciculata and adrenal weight reduction in older men. J. Clin. Endocrinol. Metab. 105, e200–e210 (2019).
doi: 10.1210/clinem/dgz214
Ludescher, B. et al. Gender specific correlations of adrenal gland size and body fat distribution: a whole body MRI study. Horm. Metab. Res. 39, 515–518 (2007).
pubmed: 17611905
doi: 10.1055/s-2007-982518
Levasseur, A., Dumontet, T. & Martinez, A. Sexual dimorphism in adrenal gland development and tumorigenesis. Curr. Opin. Endocr. Metab. Res. 8, 60–65 (2019).
doi: 10.1016/j.coemr.2019.07.008
Lacroix, A., Feelders, R. A., Stratakis, C. A. & Nieman, L. K. Cushing’s syndrome. Lancet 386, 913–927 (2015).
pubmed: 26004339
doi: 10.1016/S0140-6736(14)61375-1
Audenet, F., Méjean, A., Chartier-Kastler, E. & Rouprêt, M. Adrenal tumours are more predominant in females regardless of their histological subtype: a review. World J. Urol. 31, 1037–1043 (2013).
pubmed: 23299088
doi: 10.1007/s00345-012-1011-1
Michalkiewicz, E. et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the international pediatric adrenocortical tumor registry. J. Clin. Oncol. 22, 838–845 (2004).
pubmed: 14990639
doi: 10.1200/JCO.2004.08.085
Sirianni, R. et al. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment. J. Clin. Endocrinol. Metab. 97, E2238–E2250 (2012).
pubmed: 23074235
doi: 10.1210/jc.2012-2374
Rossi, R. et al. Evidence for androgen receptor gene expression and growth inhibitory effect of dihydrotestosterone on human adrenocortical cells. J. Endocrinol. 159, 373–380 (1998).
pubmed: 9834454
doi: 10.1677/joe.0.1590373
Crona, J. & Beuschlein, F. Adrenocortical carcinoma — towards genomics guided clinical care. Nat. Rev. Endocrinol. 15, 548–560 (2019).
pubmed: 31147626
doi: 10.1038/s41574-019-0221-7
Else, T. et al. Adrenocortical carcinoma. Endocr. Rev. 35, 282–326 (2014).
pubmed: 24423978
doi: 10.1210/er.2013-1029
Borges, K. S. et al. Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice. Oncogene 39, 5282–5291 (2020).
pubmed: 32561853
pmcid: 7378041
doi: 10.1038/s41388-020-1358-5
Jouinot, A., Armignacco, R. & Assié, G. Genomics of benign adrenocortical tumors. J. Steroid Biochem. Mol. Biol. 193, 105414 (2019).
pubmed: 31207362
doi: 10.1016/j.jsbmb.2019.105414
Goh, G. et al. Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nat. Genet. 46, 613–617 (2014).
pubmed: 24747643
pmcid: 4074779
doi: 10.1038/ng.2956
Sato, Y. et al. Recurrent somatic mutations underlie corticotropin-independent Cushing’s syndrome. Science 344, 917–920 (2014).
pubmed: 24855271
doi: 10.1126/science.1252328
Cao, Y. et al. Activating hotspot L205R mutation in PRKACA and adrenal Cushing’s syndrome. Science 344, 913–917 (2014).
pubmed: 24700472
doi: 10.1126/science.1249480
Beuschlein, F. et al. Constitutive activation of PKA catalytic subunit in adrenal Cushing’s syndrome. N. Engl. J. Med. 370, 1019–1028 (2014).
pubmed: 24571724
pmcid: 4727447
doi: 10.1056/NEJMoa1310359
Horvath, A., Mericq, V. & Stratakis, C. A. Mutation in PDE8B, a cyclic AMP–specific phosphodiesterase in adrenal hyperplasia. N. Engl. J. Med. 358, 750–752 (2008).
pubmed: 18272904
doi: 10.1056/NEJMc0706182
Kirschner, L. S. et al. Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex. Nat. Genet. 26, 89–92 (2000).
pubmed: 10973256
doi: 10.1038/79238
Bertherat, J. et al. Mutations in regulatory subunit type 1A of cyclic adenosine 5′-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J. Clin. Endocrinol. Metab. 94, 2085–2091 (2009).
pubmed: 19293268
pmcid: 2690418
doi: 10.1210/jc.2008-2333
Sahut-Barnola, I. et al. Cushing’s syndrome and fetal features resurgence in adrenal cortex-specific Prkar1a knockout mice. PLoS Genet. 6, 1–16 (2010).
doi: 10.1371/journal.pgen.1000980
Ronchi, C. L. et al. Genetic landscape of sporadic unilateral adrenocortical adenomas without PRKACA p.Leu206Arg mutation. J. Clin. Endocrinol. Metab. 101, 3526–3538 (2016).
pubmed: 27389594
doi: 10.1210/jc.2016-1586
Åkerström, T. et al. Activating mutations in CTNNB1 in aldosterone producing adenomas. Sci. Rep. 6, 19546 (2016).
pubmed: 26815163
pmcid: 4728393
doi: 10.1038/srep19546
Bonnet, S. et al. Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors. J. Clin. Endocrinol. Metab. 96, E419–E426 (2011).
pubmed: 21084400
doi: 10.1210/jc.2010-1885
Berthon, A. et al. Age-dependent effects of Armc5 haploinsufficiency on adrenocortical function. Hum. Mol. Genet. 26, 3495–3507 (2017).
pubmed: 28911199
pmcid: 6074838
doi: 10.1093/hmg/ddx235
St-Jean, M., Ghorayeb, N. E. L., Bourdeau, I. & Lacroix, A. Aberrant G-protein coupled hormone receptor in adrenal diseases. Best Pract. Res. Clin. Endocrinol. Metab. 32, 165–187 (2018).
pubmed: 29678284
doi: 10.1016/j.beem.2018.01.003
Lacroix, A., Hamet, P. & Boutin, J.-M. Leuprolide acetate therapy in luteinizing hormone–dependent Cushing’s syndrome. N. Engl. J. Med. 341, 1577–1581 (1999).
pubmed: 10564687
doi: 10.1056/NEJM199911183412104
Rao, C. V., Zhou, X. L. & Lei, Z. M. Functional luteinizing hormone/chorionic gonadotropin receptors in human adrenal cortical H295R cells. Biol. Reprod. 71, 579–587 (2004).
pubmed: 15084485
doi: 10.1095/biolreprod.104.027300
Pabon, J. E. et al. Novel presence of luteinizing hormone/chorionic gonadotropin receptors in human adrenal glands. J. Clin. Endocrinol. Metab. 81, 2397–2400 (1996).
pubmed: 8964884
Beuschlein, F. et al. Activin induces X-zone apoptosis that inhibits luteinizing hormone-dependent adrenocortical tumor formation in inhibin-deficient mice. Mol. Cell. Biol. 23, 3951–3964 (2003).
pubmed: 12748296
pmcid: 155220
doi: 10.1128/MCB.23.11.3951-3964.2003
Johnsen, I. K. et al. Gonadectomy in mice of the inbred strain CE/J induces proliferation of sub-capsular adrenal cells expressing gonadal marker genes. J. Endocrinol. 190, 47–57 (2006).
pubmed: 16837610
doi: 10.1677/joe.1.06750
Doroszko, M. et al. Luteinizing hormone and GATA4 action in the adrenocortical tumorigenesis of gonadectomized female mice. Cell. Physiol. Biochem. 43, 1064–1076 (2017).
pubmed: 28977799
doi: 10.1159/000481718
Chrusciel, M. et al. Transgenic GATA-4 expression induces adrenocortical tumorigenesis in C57BL/6 mice. J. Cell Sci. 126, 1845–1857 (2013).
pubmed: 23444372
pmcid: 3678410
Saner-Amigh, K. et al. Elevated expression of luteinizing hormone receptor in aldosterone- producing adenomas. J. Clin. Endocrinol. Metab. 91, 1136–1142 (2006).
pubmed: 16332935
doi: 10.1210/jc.2005-1298
Ye, P., Mariniello, B., Mantero, F., Shibata, H. & Rainey, W. E. G-protein-coupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism. J. Endocrinol. 195, 39–48 (2007).
pubmed: 17911395
doi: 10.1677/JOE-07-0037
Zheng, S. et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell 29, 723–736 (2016).
pubmed: 27165744
pmcid: 4864952
doi: 10.1016/j.ccell.2016.04.002
Assié, G. et al. Integrated genomic characterization of adrenocortical carcinoma. Nat. Genet. 46, 607–612 (2014).
pubmed: 24747642
doi: 10.1038/ng.2953
Juhlin, C. C. et al. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 100, E493–E502 (2015).
pubmed: 25490274
doi: 10.1210/jc.2014-3282
Fiorentini, C. et al. Molecular drivers of potential immunotherapy failure in adrenocortical carcinoma. J. Oncol. 2019, 6072863 (2019).
pubmed: 31057613
pmcid: 6463568
doi: 10.1155/2019/6072863
Habra, M. A. et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J. Immunother. Cancer 7, 253 (2019).
pubmed: 31533818
pmcid: 6751592
doi: 10.1186/s40425-019-0722-x
Shang, S., Hua, F. & Hu, Z. W. The regulation of β-catenin activity and function in cancer: therapeutic opportunities. Oncotarget 8, 33972–33989 (2017).
pubmed: 28430641
pmcid: 5464927
doi: 10.18632/oncotarget.15687
Krishnamurthy, N. & Kurzrock, R. Targeting the Wnt/β-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat. Rev. 62, 50–60 (2018).
pubmed: 29169144
doi: 10.1016/j.ctrv.2017.11.002
Madan, B. et al. Wnt addiction of genetically defined cancers reversed by PORCN inhibition. Oncogene 35, 2197–2207 (2016).
pubmed: 26257057
doi: 10.1038/onc.2015.280
Zhong, Z. et al. PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers. Oncogene 38, 6662–6677 (2019).
pubmed: 31391551
doi: 10.1038/s41388-019-0908-1
Koo, B. K., Van Es, J. H., Van Den Born, M. & Clevers, H. Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3-mutant neoplasia. Proc. Natl Acad. Sci. USA 112, 7548–7550 (2015).
pubmed: 26023187
doi: 10.1073/pnas.1508113112
Gurney, A. et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc. Natl Acad. Sci. USA 109, 11717–11722 (2012).
pubmed: 22753465
doi: 10.1073/pnas.1120068109
Fischer, M. M. et al. WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Sci. Adv. 3, e1700090 (2017).
pubmed: 28691093
pmcid: 5479655
doi: 10.1126/sciadv.1700090
Hallett, R. M. et al. Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer. PLoS ONE 7, e33976 (2012).
pubmed: 22470504
pmcid: 3314694
doi: 10.1371/journal.pone.0033976
Gandhirajan, R. K. et al. Small molecule inhibitors of Wnt/β-Catenin/Lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia 12, 326–335 (2010).
pubmed: 20360943
pmcid: 2847740
doi: 10.1593/neo.91972
Trosset, J. Y. et al. Inhibition of protein-protein interactions: the discovery of druglike β-catenin inhibitors by combining virtual and biophysical screening. Proteins Struct. Funct. Genet. 64, 60–67 (2006).
pubmed: 16568448
doi: 10.1002/prot.20955
Leal, L. F. et al. Inhibition of the Tcf/β-catenin complex increases apoptosis and impairs adrenocortical tumor cell proliferation and adrenal steroidogenesis. Oncotarget 6, 43016–43032 (2015).
pubmed: 26515592
pmcid: 4767488
doi: 10.18632/oncotarget.5513
Rimkus, T., Carpenter, R., Qasem, S., Chan, M. & Lo, H.-W. Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors. Cancers 8, 22 (2016).
pmcid: 4773745
doi: 10.3390/cancers8020022
Charmandari, E., Nicolaides, N. C. & Chrousos, G. P. Adrenal insufficiency. Lancet 383, 2152–2167 (2014).
pubmed: 24503135
doi: 10.1016/S0140-6736(13)61684-0
Achermann, J. C., Ito, M., Ito, M., Hindmarsh, P. C. & Jameson, J. L. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat. Genet. 22, 125–126 (1999).
pubmed: 10369247
doi: 10.1038/9629
Hughes, C. R. et al. MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J. Clin. Invest. 122, 814–820 (2012).
pubmed: 22354170
pmcid: 3287227
doi: 10.1172/JCI60224
Prasad, R. et al. Thioredoxin reductase 2 (TXNRD2) mutation associated with familial glucocorticoid deficiency (FGD). J. Clin. Endocrinol. Metab. 99, E1556–E1563 (2014).
pubmed: 24601690
pmcid: 4207928
doi: 10.1210/jc.2013-3844
Meimaridou, E. et al. Mutations in NNT encoding nicotinamide nucleotide transhydrogenase cause familial glucocorticoid deficiency. Nat. Genet. 44, 740–742 (2012).
pubmed: 22634753
pmcid: 3386896
doi: 10.1038/ng.2299
Handschug, K. et al. Triple A syndrome is caused by mutations in AAAS, a new WD-repeat protein gene. Hum. Mol. Genet. 10, 283–290 (2001).
pubmed: 11159947
doi: 10.1093/hmg/10.3.283
Bergthorsdottir, R., Leonsson-Zachrisson, M., Odén, A. & Johannsson, G. Premature mortality in patients with Addison’s disease: a population-based study. J. Clin. Endocrinol. Metab. 91, 4849–4853 (2006).
pubmed: 16968806
doi: 10.1210/jc.2006-0076
Gan, E. H. & Pierce, S. H. Regenerative therapies in autoimmune Addison’s disease. Eur. J. Endocrinol. 3, R123–R135 (2017).
doi: 10.1530/EJE-16-0581
Ruiz-Babot, G., Hadjidemetriou, I., King, P. J. & Guasti, L. New directions for the treatment of adrenal insufficiency. Front. Endocrinol. 6, 70 (2015).
doi: 10.3389/fendo.2015.00070
Sonoyama, T. et al. Differentiation of human embryonic stem cells and human induced pluripotent stem cells into steroid-producing cells. Endocrinology 153, 4336–4345 (2012).
pubmed: 22778223
doi: 10.1210/en.2012-1060
Li, L. et al. Directing differentiation of human induced pluripotent stem cells toward androgen-producing Leydig cells rather than adrenal cells. Proc. Natl Acad. Sci. USA 116, 23274–23283 (2019).
pubmed: 31591190
doi: 10.1073/pnas.1908207116
Smans, L. C. C. J. & Zelissen, P. M. J. Partial recovery of adrenal function in a patient with autoimmune Addison’s disease. J. Endocrinol. Invest. 31, 672–674 (2008).
pubmed: 18787390
doi: 10.1007/BF03345623
Baxter, M., Gorick, S. & Swords, F. M. Recovery of adrenal function in a patient with confirmed Addison’s disease. Endocrinol. Diabetes Metab. Case Rep. 2013, 130070 (2013).
pubmed: 24683477
pmcid: 3965278
Chakera, A. J. & Vaidya, B. Spontaneously resolving Addison’s disease. QJM 105, 1113–1115 (2012).
pubmed: 21908862
doi: 10.1093/qjmed/hcr162
Poirier, J. et al. Recovery of adrenal insufficiency is frequent after adjuvant mitotane therapy in patients with adrenocortical carcinoma. Cancers 12, 639 (2020).
pmcid: 7139486
doi: 10.3390/cancers12030639
Baker, P. R. et al. Predicting the onset of Addison’s disease: ACTH, renin, cortisol and 21-hydroxylase autoantibodies. Clin. Endocrinol. 76, 617–624 (2012).
doi: 10.1111/j.1365-2265.2011.04276.x
Fassnacht, M., Libé, R., Kroiss, M. & Allolio, B. Adrenocortical carcinoma: a clinician’s update. Nat. Rev. Endocrinol. 7, 323–335 (2011).
pubmed: 21386792
doi: 10.1038/nrendo.2010.235
Luton, J. P. et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N. Engl. J. Med. 322, 1195–1201 (1990).
pubmed: 2325710
doi: 10.1056/NEJM199004263221705
Lindholm, J. et al. Incidence and late prognosis of Cushing’s syndrome: a population-based study 1. J. Clin. Endocrinol. Metab. 86, 117–123 (2001).
pubmed: 11231987
Steffensen, C., Bak, A. M., Zøylner Rubeck, K. & Jørgensen, J. O. L. Epidemiology of Cushing’s syndrome. Neuroendocrinology 92, 1–5 (2010).
pubmed: 20829610
doi: 10.1159/000314297
Stratakis, C. Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin-independent Cushing syndrome). Endocr. Dev. 13, 117–132 (2008).
pubmed: 18493137
pmcid: 3132884
doi: 10.1159/000134829
Kong, M.-F. & Jeffcoate, W. Eighty-six cases of Addison’s disease. Clin. Endocrinol. 41, 757–761 (1994).
doi: 10.1111/j.1365-2265.1994.tb02790.x
Myhre, A. G. et al. Autoimmune adrenocortical failure in norway autoantibodies and human leukocyte antigen class II associations related to clinical features. J. Clin. Endocrinol. Metab. 87, 618–623 (2002).
pubmed: 11836294
doi: 10.1210/jcem.87.2.8192
Heaton, J. H. et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin. Am. J. Pathol. 181, 1017–1033 (2012).
pubmed: 22800756
pmcid: 3432433
doi: 10.1016/j.ajpath.2012.05.026
Engeland, W. C. et al. Sex differences in adrenal Bmal1 deletion-induced augmentation of glucocorticoid responses to stress and ACTH in mice. Endocrinology 160, 2215–2229 (2019).
pubmed: 31398249
pmcid: 6735739
doi: 10.1210/en.2019-00357
Lambert-Langlais, S. et al. A transgenic mouse line with specific Cre recombinase expression in the adrenal cortex. Mol. Cell. Endocrinol. 300, 197–204 (2009).
pubmed: 19041690
doi: 10.1016/j.mce.2008.10.045
Mandel, H. et al. SERKAL syndrome: an autosomal-recessive disorder caused by a loss-of-function mutation in WNT4. Am. J. Hum. Genet. 82, 39–47 (2008).
pubmed: 18179883
pmcid: 2253972
doi: 10.1016/j.ajhg.2007.08.005
Heikkilä, M. et al. Wnt-4 deficiency alters mouse adrenal cortex function, reducing aldosterone production. Endocrinology 143, 4358–4365 (2002).
pubmed: 12399432
doi: 10.1210/en.2002-220275